Arbutus alleges that Moderna’s COVID-19 vaccine infringes on patents protecting its lipid nanoparticle delivery technology.

In a competitive job market, how applicants present themselves in interviews is critical. Asking about promotions and ...

Following the successful late-stage study in wet age-related macular degeneration, Ocular plans to meet with the FDA to ...

Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...

Many scientists-turned-CEOs paradoxically abandon scientific principles when it comes to commercializing their innovations.

PitchBook’s 2025 biopharma VC analysis clocked $33.8 billion in capital dispatched in 2025, mainly to companies with ...

Jay Bhattacharya will become the latest leader of the CDC on an acting basis, days after Jim O’Neill stepped aside.

With leaner teams and tighter budgets, senior leaders can face tremendous strain as they juggle increased workloads and leadership responsibilities. In this column, Kaye/Bassman’s Michael Pietrack ...

Once fully operational, the Pennsylvania site will employ more than 500 people and make cell therapies for thousands of patients a year.

After the FDA’s decision to reject a review of Moderna’s mRNA-1010 flu shot, executives explain what Americans will miss out ...

In this episode of Denatured, you'll be listening to Jane Hughes, President of R&D and Co-founder of Verdiva Bio, and Jon Rees, CEO and Co-founder of MitoRx Therapeutics. We'll discuss next-generation ...

Drug sponsors should nevertheless bolster their application with “confirmative evidence,” chief regulators Marty Makary and Vinay Prasad said on Wednesday, including mechanistic data or findings from ...